Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance
Chia-Ping Huang Yang1,2, Changwei Wang3, Iwao Ojima3
1Department of Molecular Pharmacology , Albert Einstein College of Medicine , Bronx , New York 10461 , United States.
Abstract:
Several next-generation taxanes have been reported to possess high potency against Taxol-resistant cancer cell lines overexpressing βIII-tubulin and/or P-glycoprotein (P-gp), both of which are involved in drug resistance. Using a photoaffinity Taxol analogue, 2-( m-azidobenzoyl)taxol, two potent next-generation taxanes, SB-T-1214 and SB-CST-10202, exhibited distinct inhibitory effects on photolabeling of β-tubulin from different eukaryotic sources that differ in β-tubulin isotype composition. They also specifically inhibited photolabeling of P-gp, and the inhibitory effect correlated well with the steady-state accumulation of [3H]vinblastine in a multidrug resistant (MDR) cell line, SKVLB1. Several microtubule-stabilizing agents (MSAs)-resistant cell lines from the human ovarian cancer cell line Hey were isolated, and their MDR1 and βIII-tubulin levels determined. Distinct potencies of the two taxanes against different MSA-resistant cells expressing unique levels of MDR1 and βIII-tubulin were found. Cytotoxicity assays, done in the presence of verapamil, indicated that SB-T-1214 is a substrate, although not as good as Taxol, for P-gp. The mechanisms involved in drug resistance are multifactorial, and the effectiveness of new Taxol analogues depends on the interaction between the drugs and all possible targets; in this case the two major cellular targets are β-tubulin and P-gp.
Insights
New taxanes, SB-T-1214 and SB-CST-10202, show potent activity against Taxol-resistant cancers by targeting βIII-tubulin and P-glycoprotein (P-gp). Their effectiveness varies based on drug resistance mechanisms in cancer cells.
Area of Science:
- Pharmacology
- Molecular Biology
- Oncology
Background:
- Taxol resistance in cancer is often mediated by βIII-tubulin overexpression and P-glycoprotein (P-gp) efflux.
- Next-generation taxanes are being developed to overcome these resistance mechanisms.
Purpose of the Study:
- To evaluate the distinct inhibitory effects of two novel taxanes, SB-T-1214 and SB-CST-10202, on β-tubulin and P-gp.
- To assess the potency of these taxanes against various multidrug-resistant (MDR) cancer cell lines.
Main Methods:
- Photoaffinity labeling with a Taxol analogue was used to study drug interactions with β-tubulin and P-gp.
- Multidrug-resistant cell lines with varying levels of MDR1 and βIII-tubulin were generated and characterized.
- Cytotoxicity assays were performed in the presence of verapamil to determine P-gp substrate activity.
Main Results:
- SB-T-1214 and SB-CST-10202 demonstrated differential inhibition of β-tubulin photolabeling across eukaryotic sources.
- Both taxanes inhibited P-gp photolabeling, correlating with [3H]vinblastine accumulation in MDR cells.
- The taxanes exhibited distinct potencies against MSA-resistant cells with varying MDR1 and βIII-tubulin expression.
- SB-T-1214 was identified as a P-gp substrate, though less so than Taxol.
Conclusions:
- The effectiveness of novel taxanes is influenced by their interaction with multiple targets, including β-tubulin isotypes and P-gp.
- SB-T-1214 and SB-CST-10202 represent promising candidates for treating cancers with specific drug resistance mechanisms.
- Understanding the interplay between drug properties and cellular resistance factors is crucial for developing effective cancer therapies.
More Related Videos
Related Concept Videos
Matrix Proteoglycans and Glycoproteins
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Resistivity
Resistance
Framing Effects
Equivalent Resistance


